PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
02-Mar-2022 Global Pain Management Drugs Market to 2030 - Featuring Abbott Laboratories, Bayer and Endo Health Solutions Among Others - ResearchAndMarkets.com Businesswire
02-Mar-2022 GlycoMimetics Appoints Deepak Tiwari, Ph.D., as new Vice President, Technical Operations Businesswire
02-Mar-2022 86% of Patients Say Wearable Devices Improve Health Outcomes, According to Software Advice Research Businesswire
02-Mar-2022 OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer Businesswire
02-Mar-2022 Swift Medical Launches the World’s First All-in-One Hyperspectral Imaging Device to Make Healthcare More Accessible Businesswire
02-Mar-2022 Caduceus Capital Partners Invests in UptimeHealth Businesswire
02-Mar-2022 PerkinElmer Launches ChemDraw® V21 Software, Empowering Researchers to Rapidly Create Chemically Intelligent Microsoft PowerPoint Reports Businesswire
02-Mar-2022 Thermo Fisher Scientific’s PPD Clinical Research Business Earns Honor for Employee Development Driving Customer Success Businesswire
02-Mar-2022 Simulations Plus to Present at Raymond James Institutional Investors Conference Businesswire
02-Mar-2022 Thermo Fisher Scientific to Present at Cowen’s 42nd Annual Healthcare Conference Businesswire
02-Mar-2022 Revance to Participate in the Cowen 42nd Annual Health Care Conference Businesswire
02-Mar-2022 TruBiotics® Grows Its Family: New Baby Drops Feature Clinically Researched Probiotic Strain BB-12® Shown to Reduce Excessive Infant Crying and Fussing, and Increase Sleep Duration Businesswire
02-Mar-2022 Graphite Bio Appoints Alethia Young as Chief Financial Officer Businesswire
02-Mar-2022 Xalud Therapeutics Doses First Patient in Phase 2a Trial of XT-150 for the Treatment of Facet Joint Osteoarthritis Pain Businesswire
02-Mar-2022 FDA Approves Kaléo’s 10 mg Naloxone Auto-Injector for the Treatment of Known or Potential Exposure to Ultra-Potent Weaponized Opioids Businesswire
02-Mar-2022 Addus HomeCare Promotes Monica Raines To Executive Vice President, Chief Compliance and Quality Officer Businesswire
02-Mar-2022 NCCN Clinical Practice Guidelines in Oncology Update Recommends BESREMi® (ropeginterferon alfa-2b-njft) for the Treatment of Polycythemia Vera Businesswire
02-Mar-2022 Innocoll Announces Positive Topline Results For XARACOLL® (bupivacaine hydrochloride) implant in a Phase 3 Study to Support Expanded Use Businesswire
02-Mar-2022 Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults Businesswire
02-Mar-2022 Teva Canada se réjouit du remboursement d’AJOVY(MD) (frémanezumab) par les régimes publics d’assurance médicaments de l’Alberta, de la Saskatchewan, du Québec ainsi que par le ACC et le Programme SSNA aux patients prescrit AJOVY(MD) Businesswire